Overview
Between February and June 2026, twelve drugs previously rated by MARA received new regulatory approvals — from the FDA or EMA — triggering a formal surveillance reassessment of each rating.
Regulatory approval is a material evidence event under the MARA Surveillance Policy. It changes the drug’s commercial and evidentiary status: new label language becomes available, post-marketing commitments are disclosed, and the comparator landscape shifts in markets where the approval creates or narrows competitive space. Each of these developments can affect the reimbursement probability signal.
This article presents the outcome of all twelve reassessments, organized by rating action.
Why Regulatory Approval Triggers a Reassessment
A regulatory approval does not automatically improve a drug’s reimbursement risk profile. The FDA and EMA assess safety and efficacy — not cost-effectiveness, not comparative value in payer-relevant terms, not budget impact.
In several cases in this batch, the approval provided additional clarity that narrowed the evidence position rather than strengthened it. In others, new label restrictions or safety signals introduced constraints that were not present at the time of the original rating.
The MARA reassessment applies the same 10-domain framework to the updated evidence base. The prior rating is not carried forward — it is re-derived from current data.
Downgrades
Camizestrant / Etcamah — ER-Positive, HER2-Negative Breast Cancer
B++ (Marginal) → B+ (Very Weak) EMA approval: May 22, 2026
The original MARA Rating for camizestrant was issued on phase 2 SERENA-2 data. The EMA approval, based on those same data, prompted a reassessment of whether the evidence base has developed sufficiently to support reimbursement arguments.
It has not. The approval rests on an open-label phase 2 trial — a design that most HTA bodies treat with caution. The primary endpoint showed improvements in time without disease progression compared to fulvestrant, but the trial was not blinded and confidence in the magnitude of benefit is limited.
More significantly, the comparator used — fulvestrant — is increasingly outdated. Elacestrant received approval in this class after the SERENA-2 trial was designed, and payers in major markets will expect head-to-head data or network meta-analytic adjustments. No economic model is available. No utility values have been published.
The rating moves to B+ (Very Weak). The evidence base does not yet support a defensible reimbursement submission in most markets.
Belumosudil / Rezurock — Chronic Graft-Versus-Host Disease
A (Strong) → B++ (Marginal) EMA approval: January 29, 2026
The original rating was based on US approval data where NICE had not yet completed its appraisal. The EMA approval now makes belumosudil subject to HTA review in European markets, and the full evidence picture at that stage is more constrained.
The ROCKstar trial demonstrated a 75% overall response rate — clinically meaningful in a condition with few remaining treatment options. However, the trial was single-arm with no randomised control. The EMA and HTA bodies must interpret this result without a direct comparator.
NICE modeling suggests the cost per outcome gained is within an acceptable range under several scenarios, but the uncertainty intervals are wide. Quality-of-life evidence is based on a symptom scale rather than utility-generating instruments, which limits how the data can be used in economic models.
The combination of uncontrolled evidence and uncertain cost-effectiveness moves the rating to B++ (Marginal). The clinical signal is credible; the access outcome will depend on pricing and country-specific negotiation.
Upgrades
BAXFENDY / baxdrostat — Resistant Hypertension
B+ (Very Weak) → B++ (Marginal) FDA approval: May 15, 2026
The FDA approval of baxdrostat confirmed a clinical signal that was previously conditional on regulatory outcome. The BaxHTN and Bax24 phase 3 trials showed placebo-corrected blood pressure reductions of 9.8 mmHg and 14.0 mmHg respectively — meaningful results in a population where standard therapies have not achieved adequate control.
The approval also triggered NICE and ICER appraisal processes, establishing a formal economic evaluation pathway that did not previously exist. While no cost-effectiveness results are yet available, the initiation of those processes reduces the structural uncertainty that contributed to the prior B+ rating.
The evidence gaps remain substantial: no long-term cardiovascular outcome data, no head-to-head comparison against spironolactone (the established standard of care), and no quality-of-life data. The improvement in rating reflects the confirmed clinical signal and the opening of the economic evaluation track — not a resolution of those gaps.
Tolebrutinib / Cenrifki — Non-Relapsing Secondary Progressive Multiple Sclerosis
B+ (Very Weak) → B++ (Marginal) EMA approval: April 24, 2026
Tolebrutinib was the first treatment to receive approval specifically in non-relapsing secondary progressive MS — a population that has historically been excluded from clinical trials and has had no approved options.
The HERCULES trial demonstrated a hazard ratio of 0.69 for confirmed disability progression — a statistically significant result in a setting where any positive result carries weight. That unmet need context, now formally recognised by the EMA, contributes to the rating improvement.
The barriers are significant. The FDA raised concerns about potential contamination of the trial population with active SPMS patients. ICER modeling placed the cost per outcome gained at $3.4 million per QALY — a figure that reflects placeholder pricing rather than a negotiated commercial position, but signals the scale of adjustment required. Quality-of-life data were planned but not reported in the main publication.
The rating moves to B++ (Marginal). The unmet need recognition by a major regulator is a material change. The economic position remains highly exposed.
Reassessed in a Revised Indication
Three drugs in this batch were previously rated by MARA in a different population or indication scope. In each case, the new regulatory approval was for a modified population — narrower, broader, or shifted — compared to the one covered by the original rating.
These are not updates of a prior rating in the conventional sense. They are new ratings applied to a drug in a distinct clinical context. A direct numerical comparison to the prior MARA Rating would be misleading, because the two ratings do not assess the same patient group.
HEPCLUDEX / bulevirtide — Chronic Hepatitis Delta in Adults Without Cirrhosis or With Compensated Cirrhosis
Prior rating: A (Strong) in chronic hepatitis D — broad population June 2026 rating: B++ (Marginal) — adults without cirrhosis or with compensated cirrhosis only EMA full approval: May 22, 2026
The prior MARA Rating was issued when bulevirtide held a conditional marketing authorisation and was assessed across the full chronic hepatitis D population. The June 2026 rating applies to the population defined by the full EMA approval: adults without cirrhosis or with compensated cirrhosis. Patients with decompensated cirrhosis are outside the scope of this rating.
This population restriction is itself a material access risk factor. A narrower eligible population limits commercial scale and makes reimbursement negotiations more difficult in markets that price on cost per patient.
On the evidence: the pivotal MYR301 phase 3 trial demonstrated a combined virological and biochemical endpoint in 45–48% of patients versus 2% in the delayed treatment arm. The signal is meaningful. However, cost-effectiveness estimates diverge sharply across jurisdictions — NICE modeling falls within acceptable range (~£27,000/QALY), while NCPE found the ICER unacceptably high (€193,273/QALY). That divergence signals a pricing corridor problem that the prior rating, issued before full approval, did not yet face.
The June 2026 rating is B++ (Marginal) for the approved population. The prior A rating applied to a broader clinical context and cannot be directly compared.
JASCAYD / nerandomilast — Idiopathic Pulmonary Fibrosis / Progressive Pulmonary Fibrosis
Prior rating: B++ (Marginal) in idiopathic pulmonary fibrosis (IPF) only June 2026 rating: B++ (Marginal) — IPF and progressive pulmonary fibrosis (PPF) EMA approval: May 22, 2026
The prior MARA Rating covered nerandomilast in IPF only. The EMA approval extends to progressive pulmonary fibrosis as well — a broader set of fibrotic lung conditions. PPF encompasses several underlying diagnoses and represents a meaningfully different patient population from IPF.
The B++ rating is affirmed, but this should be read as a new assessment across both indications — not a confirmation that the IPF rating is unchanged. The economic evidence package remains entirely absent for both indications. No cost-utility model has been filed with any HTA body. The clinical signal — preservation of lung function versus placebo, with FVC decline differences of 48–64 mL — is supported by phase 3 data and is meaningful in a disease with few treatment options.
The June 2026 rating covers the full approved scope. Teams planning HTA submissions for either indication separately should expect the evidence to be assessed in that narrower context.
Foundayo / orforglipron — Overweight and Obesity
Prior rating: B++ (Marginal) in obesity combined with type 2 diabetes June 2026 rating: B++ (Marginal) — overweight and obesity without the T2D indication FDA approval: April 1, 2026
The prior MARA Rating assessed orforglipron in the context of obesity and type 2 diabetes. The June 2026 rating covers the overweight and obesity indication only. These are different clinical populations with different HTA comparator sets, different payer willingness-to-pay benchmarks, and different reimbursement pathways in most markets.
The B++ rating is the same numerical output, but the two assessments are not comparable. The obesity-only population faces a more competitive market — semaglutide and tirzepatide are both established with robust HTA records — and no head-to-head comparison against either has been conducted. A conference-poster ICER estimate of $161,466/QALY remains the only public cost-effectiveness data point and is well above standard thresholds.
The June 2026 rating is B++ for the obesity indication specifically. The prior T2D-inclusive rating remains a separate assessment.
Affirmed
Five ratings were reviewed and confirmed without change. In each case, the regulatory approval did not materially alter the evidence profile in ways that would shift the reimbursement risk signal.
Wegovy / Semaglutide — Weight Management | A → A The EMA approval (May 22, 2026) confirms a position already well-supported by phase 3 evidence and existing reimbursement outcomes in key markets. The evidence base is mature and the economic case, while marginal, is defensible.
Redemplo / plozasiran — Familial Chylomicronemia Syndrome | B++ → B++ EMA approval (April 24, 2026) on surrogate triglyceride endpoint. No pancreatitis event data. No cost model. Competitive space now occupied by olezarsen in the same indication.
Imdylltra / tarlatamab — Relapsed Extensive-Stage SCLC | B++ → B++ EMA approval (March 27, 2026). Single-arm evidence base unchanged. NICE and CDA-AMC ICERs remain above acceptable thresholds. Commercial arrangement negotiations ongoing.
Palsonify / paltusotine — Acromegaly | B+ → B+ EMA approval (February 27, 2026). The pivotal trial demonstrated biochemical control versus placebo, but HTA bodies will expect comparison against injectable somatostatin analogues — the established standard of care. That comparison does not exist. No cost model available.
Rhapsido / remibrutinib — Chronic Spontaneous Urticaria | B++ → B++ EMA approval (February 27, 2026). Phase 3 evidence versus placebo is solid, but no head-to-head against omalizumab — the established biological — has been conducted. No completed economic model is available.
Structural Observation
Across this batch of twelve regulatory-triggered reassessments, four patterns are consistent.
First, regulatory approval does not resolve the access question. Two of the twelve drugs were downgraded following a formal approval — a reminder that the evidentiary standard for market authorisation and the standard for reimbursement are not the same.
Second, population scope matters as much as evidence quality. Three drugs in this batch cannot be compared directly to their prior ratings because the approved population shifted. Narrower populations reduce commercial scale. Broader populations require evidence that covers all subgroups. Either direction introduces new HTA risk that a prior rating — issued in a different context — could not have captured.
Third, the economic evidence package lags behind the regulatory dossier in nearly every case. Of the twelve drugs, only semaglutide has a mature, publicly submitted cost-effectiveness analysis. For the remaining eleven, the economic case is either absent, incomplete, or based on modelling too early-stage to be defensible under HTA scrutiny.
Fourth, affirmation at the same rating band is itself a signal. Five drugs were reviewed and confirmed at their prior rating level. This means that a regulatory milestone — typically treated internally as a positive development — did not change the reimbursement risk profile. Teams planning market access strategy around approval timelines should account for this.
Methodological Note
All reassessments apply the MARA 10-domain framework to updated publicly available evidence. Prior ratings are not carried forward. Each reassessment is conducted independently, with the same framework applied regardless of the direction of change. Inter-rater consistency is enforced as a structural requirement: a second independent assessor reviews all rating changes before publication.
These ratings reflect reimbursement probability under HTA frameworks. They are not regulatory opinions.
MARA will continue to monitor material evidence events and adjust the reimbursement risk signal accordingly.
Browse the full MARA Ratings Catalogue → mararating.com/mara-ratings-list
MARA Rating Company AG | Independent Reimbursement Risk Assessments | mararating.com